Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 16, 2024

BUY
$101.21 - $166.61 $44,937 - $73,974
444 Added 1.72%
26,328 $3.13 Million
Q1 2024

May 15, 2024

SELL
$85.37 - $115.44 $101,931 - $137,835
-1,194 Reduced 4.41%
25,884 $2.76 Million
Q4 2023

Feb 14, 2024

SELL
$69.51 - $104.43 $21,965 - $32,999
-316 Reduced 1.15%
27,078 $2.69 Million
Q3 2023

Nov 14, 2023

SELL
$96.41 - $126.61 $328,179 - $430,980
-3,404 Reduced 11.05%
27,394 $2.83 Million
Q2 2023

Aug 14, 2023

SELL
$118.5 - $160.53 $163,648 - $221,691
-1,381 Reduced 4.29%
30,798 $3.74 Million
Q1 2023

May 15, 2023

BUY
$135.66 - $197.02 $77,597 - $112,695
572 Added 1.81%
32,179 $4.94 Million
Q4 2022

Feb 13, 2023

BUY
$118.38 - $210.04 $561,121 - $995,589
4,740 Added 17.64%
31,607 $5.68 Million
Q3 2022

Nov 14, 2022

SELL
$118.07 - $194.18 $1.48 Million - $2.43 Million
-12,510 Reduced 31.77%
26,867 $3.18 Million
Q2 2022

Aug 15, 2022

BUY
$117.13 - $176.59 $3.52 Million - $5.3 Million
30,010 Added 320.38%
39,377 $5.63 Million
Q1 2022

May 16, 2022

SELL
$126.46 - $235.05 $416,812 - $774,724
-3,296 Reduced 26.03%
9,367 $1.61 Million
Q4 2021

Feb 14, 2022

SELL
$225.82 - $368.51 $3.44 Million - $5.62 Million
-15,244 Reduced 54.62%
12,663 $3.22 Million
Q3 2021

Nov 15, 2021

SELL
$221.9 - $484.47 $10.9 Million - $23.8 Million
-49,163 Reduced 63.79%
27,907 $10.7 Million
Q2 2021

Aug 12, 2021

BUY
$129.91 - $234.98 $935,481 - $1.69 Million
7,201 Added 10.31%
77,070 $18.1 Million
Q1 2021

May 17, 2021

BUY
$109.18 - $185.98 $2.17 Million - $3.69 Million
19,859 Added 39.71%
69,869 $9.15 Million
Q4 2020

Feb 16, 2021

BUY
$65.74 - $169.86 $3.29 Million - $8.49 Million
50,010 New
50,010 $5.23 Million

Others Institutions Holding MRNA

About Moderna, Inc.


  • Ticker MRNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 391,200,000
  • Market Cap $14.4B
  • Description
  • Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, resp...
More about MRNA
Track This Portfolio

Track Parus Finance (Uk) LTD Portfolio

Follow Parus Finance (Uk) LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Parus Finance (Uk) LTD, based on Form 13F filings with the SEC.

News

Stay updated on Parus Finance (Uk) LTD with notifications on news.